Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the evidence, licences and clinical reality actually show
The biggest misconception worth correcting first: they are not competing weight-loss options
The most common misunderstanding driving searches for this comparison is the assumption that Wegovy and Trulicity are two different weight-loss injections and you are picking between them. They are not. Trulicity (dulaglutide, Eli Lilly) is a once-weekly GLP-1 receptor agonist prescribed for blood-sugar control in adults with type 2 diabetes. It has solid evidence in that indication. It has no MHRA weight-management licence, no NICE weight-loss technology appraisal, and it is not prescribed for obesity in UK clinical practice.
Wegovy, by contrast, exists specifically for weight management. Novo Nordisk developed the 2.4mg semaglutide dose and the Wegovy brand precisely because the diabetes-treatment doses of semaglutide (sold as Ozempic) produced meaningful weight loss in trials and a higher-dose, weight-focused formulation was clinically justified. The MHRA licensed Wegovy for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure or type 2 diabetes. You can read more about how Wegovy works and what the licence covers if that background is useful.
So if you have type 2 diabetes and your GP has mentioned Trulicity as a diabetes medicine, that is an entirely separate conversation from weight management through a licensed weight-loss treatment. If your interest is weight loss, Trulicity is not the medicine this page can help you access, and reputable prescribers will not prescribe it off-licence for that purpose when licensed alternatives exist.
How Wegovy and Trulicity compare on mechanism, evidence and licensed use
Both medicines activate GLP-1 receptors, which is why they appear together in searches. GLP-1 agonists reduce appetite, slow gastric emptying and help regulate blood sugar. The similarity ends around the dose and the clinical intent. Dulaglutide (Trulicity) tops out at 4.5mg weekly for diabetes; semaglutide in Wegovy reaches 2.4mg weekly for weight management, with a slower titration schedule designed for tolerability over months rather than glycaemic targets.
On weight outcomes, the STEP 1 trial (a 68-week study of semaglutide 2.4mg published in the New England Journal of Medicine) showed an average body-weight reduction of around 15% among participants without diabetes. Trulicity trials were designed around HbA1c reduction, not body-weight reduction, and they were not powered or structured to answer the weight-management question Wegovy was built to answer.
The table below captures the key factual differences.
| Feature | Wegovy (semaglutide 2.4mg) | Trulicity (dulaglutide) |
|---|---|---|
| UK licence | Weight management (BMI ≥30, or ≥27 with comorbidity) | Type 2 diabetes only |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Made by | Novo Nordisk | Eli Lilly |
| Average weight loss in trials | ~15% over 68 weeks (STEP 1, NEJM) | Not a licensed weight-loss indication; weight data not the primary endpoint |
| NICE weight-loss appraisal | Yes, TA875 | No |
| Private weight-loss prescription available | Yes, where clinically suitable | No |
If you are curious how Wegovy sits alongside other licensed options, the broader GLP-1 comparison for weight loss covers that picture clearly.
If you are considering Wegovy for weight management, here is what matters
Wegovy is a prescription-only medicine. You cannot simply order it, a prescriber reviews your health history, current medicines, BMI and any existing conditions before deciding whether it is appropriate. The process at nume involves a free consultation that a GPhC-registered Independent Prescriber personally reviews the same day; there is no algorithm making that decision. If you are curious about what clinical review involves, our clinical team page explains how the service is structured.
We know that researching weight-loss injections online can feel a little overwhelming, particularly when results pages mix licensed medicines, diabetes drugs and products with no UK approval into the same conversation. That is a reasonable source of frustration. The honest answer here is that Trulicity is simply not part of the weight-management picture in UK clinical practice, and any comparison that positions it as an alternative to Wegovy for that purpose is misleading.
Side effects for GLP-1 medicines as a class tend to be gastrointestinal: nausea, looser stools, reflux and reduced appetite are the most commonly reported. These typically ease as your body adjusts. The NHS patient information page for semaglutide covers what to expect in plain language. For a sense of how Wegovy's costs sit in the private market, the Wegovy cost page explains what legitimate pricing includes.
If you are also considering tirzepatide (Mounjaro), which is the other licensed weight-management injection in the UK and works on both GLP-1 and GIP receptors, comparing the semaglutide options or looking at newer molecules like retatrutide may be relevant depending on where your research is heading, and if next-generation combinations are on your radar, how cagrisema compares to Wegovy is worth reading before that conversation with your prescriber. Which treatment suits you is a clinical decision our prescribers work through with you, not something a comparison page can resolve.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.